Blood. 2008 Feb 15;111(4):1774-80. Epub 2007 Nov 30.
Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods.
Kantarjian H, Schiffer C, Jones D, Cortes J.
Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA. hkantarj@mdanderson.org
PMID: 18055868 [PubMed - indexed for MEDLINE]
Publication Types:
MeSH Terms:
- Chromosome Banding
- DNA Mutational Analysis
- Drug Monitoring
- Enzyme Inhibitors/therapeutic use*
- Gene Rearrangement
- Humans
- In Situ Hybridization, Fluorescence
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy*
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics*
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/physiopathology
- Polymerase Chain Reaction
- Protein-Tyrosine Kinases/antagonists & inhibitors*
Substances:
Full Text Sources:
Other Literature Sources: